Passage Bio (NYSE:GFL) Price Target Raised to $29.00 at TD Securities
Passage Bio (NYSE:GFL) had its price objective boosted by TD Securities from $27.00 to $29.00 in a research note released on Friday, The Fly reports. TD Securities currently has a hold rating on the stock.
Other equities analysts have also issued research reports about the company. Barclays started coverage on Passage Bio in a research report on Monday, March 30th. They issued an equal weight rating and a $20.00 price target for the company. CIBC increased their price target on Passage Bio from $27.00 to $28.00 and gave the company a neutral rating in a research report on Wednesday, May 13th. Stifel Nicolaus began coverage on Passage Bio in a research report on Monday, March 30th. They set a buy rating and a $26.00 price objective for the company. National Bank Financial began coverage on Passage Bio in a research report on Tuesday, April 14th. They set an outperform rating for the company. Finally, Raymond James began coverage on Passage Bio in a research report on Monday, March 30th. They set an outperform rating and a $18.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $23.05.
NYSE:GFL opened at $18.75 on Friday. Passage Bio has a 1-year low of $11.92 and a 1-year high of $20.97. The company has a fifty day moving average of $18.37.
About Passage Bio
GFL Environmental Inc operates as a diversified environmental services company in North America. The company offers non-hazardous solid waste management, infrastructure and soil remediation, and liquid waste management services. Its solid waste management business line includes the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste for municipal, residential, and commercial and industrial customers.
Featured Story: Discount Rate
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.